Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis

British Journal of Pharmacology

Volumn 157, Issue 2, 2009, Pages 258-270

  Hennenberg, M ^a,b   Trebicka, J ^a   Stark, C ^a   Kohistani, A Z ^a   Heller, J ^a   Sauerbruch, T ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Medizinische Klinik and Poliklinik I   (Germany)

Author keywords

Cholestasis; Chronic liver disease; Hepatic cirrhosis; Hepatic stellate cells; Intrahepatic microcirculation; Portal hypertension; Rho kinase; Sorafenib; Vasocontractlon

Indexed keywords

BETA ARRESTIN; MESSENGER RNA; RHO KINASE; SORAFENIB; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BILIARY CIRRHOSIS; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME REGULATION; HEMODYNAMICS; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; VASCULAR RESISTANCE; ANIMAL; AORTA; DRUG EFFECT; ENZYMOLOGY; LIVER; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; AORTA; BENZENESULFONATES; BLOTTING, WESTERN; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 68549130635     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00158.x     Document Type: Article

References (50)

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et. al. (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300.
2. Adnane L, Trail PA, Taylor I, Wilhelm SM (2006). Sorafenib (Bay 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612. (Pubitemid 43815979)
3. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
4. Anegawa G, Kawanaka H, Yoshida D, Konishi K, Yamaguchi S, Kinjo N et al (2008). Defective endothelial nitric oxide synthase signaling is mediated by Rho-kinase activation in rats with secondary biliary cirrhosis. Hepatology 47: 1-12.
5. Borkham-Kamphorst E, Kovalenko E, van Roeyen CR, Gassier N, Bomble M, Ostendorf T et al (2008). Platelet-derived growth factor isoform expression in carbon tetrachloride-induced liver injury. Lab Invest 88: 1090-1100.
6. Defea K (2008). Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br f Pharmacol 153: S298-S309.
7. de Godoy MA, Patel CA, Waldman SA, Katsuki M, Regan RF, Rattan S (2007). H-ras inhibits RhoA/ROCK leading to a decrease in the basal tone in the internal anal sphincter. Gastroenterology 132: 14011409. (Pubitemid 46656253)
8. Fukushima M, Nakamuta M, Kohjima M, Kotoh K, Enjoji M, Kobayashi N et al. (2005). Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances Collagenase activity in hepatic stellate cells. Liver Int 25: 829-838. (Pubitemid 41038664)
9. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008). Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99: 159-165. (Pubitemid 350239045)
10. Groszmann RJ, Abraldes JG (2005). Portal Hypertension. From Bedside to Bench. J. Clin Gastroenterol 39: S125-S130.
11. Häkkinen JP, Miller MW, Smith AH, Knight DR (1995). Measurement of organ blood flow with coloured microspheres in the rat. Cardiovasc Res 29: 74-79.
12. Heldin P, Pertoft H, Nordlinder H, Heldin CH, Laurent TC (1991). Differential expression of platelet-derived growth factor alpha- and beta-receptors on fat-storing cells and endothelial cells of rat liver. Exp Cell Res 193: 364-369. (Pubitemid 121005677)
13. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M et al. (2006). Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 130: 838-854. (Pubitemid 43374532)
14. Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J (2007). Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 45: 495-506. (Pubitemid 46374606)
15. Hennenberg M, Trebicka J, Sauerbruch T, Heller J (2008). Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 57: 1300-1314.
16. Hemandez-Guerra M, Garcia-Pagan JC, Bosch J (2005). Increased hepatic resistance. A new target in the pharmacologic therapy of portal hypertension. J. Clin Gastroenterol 39: S131-S137.
17. lkeda H, Nagashima K, Yanase M, Tomiya T, Arai M, Inoue Y et al. (2003). Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 285: G880-G886.
18. Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H (2000). A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol 32: 762-770. (Pubitemid 30262736)
19. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA et al (2007). Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6: 1785-1792. (Pubitemid 46954055)
20. Kitamura K, Tada S, Nakamoto N, Toda K, Horikawa H, Kurita S et al (2007). Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J. Gastroenterol Hepatol 22: 2022-2033. (Pubitemid 47525076)
21. 2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 292: G556-G564.
22. Lefkowitz RJ, Rajagopal K, Whalen EJ (2006). New roles for β-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell 24: 643-652. (Pubitemid 44839219)
23. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858. (Pubitemid 46094197)
24. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
25. Loirand G, Guerin P, Pacaud P (2006). Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98: 322-334. (Pubitemid 43755328)
26. Mehta PK, Griendling KK (2007). Angiotensin II signaling: physiological and pathophysiological effects in the cardiovascular system. Am J. Physiol Cell Physiol 292: C82-C97.
27. Moller S, Henriksen JH (2008). Cardiovascular complications of cirrhosis. Gut 57: 268-278.
28. Murata T, Arii S, Nakamura T, Mori A, Kaido T, Furuyama H et al (2001). Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol 35: 474-4781. (Pubitemid 32964446)
29. Pawlak G, Helfman DM (2002a). MEK mediates v-Src-induced disruption of the actin cytoskeleton of the Rho-ROCK-LIM kinase pathway. J Biol Chem 277: 26927-26933. (Pubitemid 34951702)
30. Pawlak G, Helfman DM (2002b). Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts. MoI Biol Cell 13: 336-347. (Pubitemid 34106079)
31. Pinzani M, Marra F (2001). Cytokine receptors and signaling in hepatic stellate cells. Semin Liv Dis 21: 397-416. (Pubitemid 32923768)
32. Rockey DC (2003). Vascular mediators in the injured liver. Hepatology 37: 4-12.
33. Seyde WC, Longnecker DE (1984). Anesthetic influence on regional hemodynamics in normal and hemorrhaged rats. Anesthesiology 61: 686-698.
34. Smith NJ, Luttrell LM. (2006). Signal switching, crosstalk, and arrestin scaffolds. Novel G protein-coupled receptor signaling in cardiovascular disease. Hypertension 48: 173-179.
35. Somlyo AP, Somlyo AV (2000). Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol 522: 177-185.
36. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83: 1325-1358.
37. Strumberg D, Clark JW, Awada A, Moore MJU, Richly H, Hendlisz A et al (2007). Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426-437. (Pubitemid 46698720)
38. Tada S, Iwamoto H, Nakamuta M, Sugimoto R, Enjoji M, Nakashima Y et al (2001). A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis In rats. J. Hepatol 34: 529-536. (Pubitemid 32328509)
39. Takimoto CH, Awada A (2008). Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61: 535-548.
40. Thomas WG, Qian H, Smith NJ (2004). When 6 is 9: 'Uncoupled' ATI receptors turn signalling on its head. CMLS 61: 2687-2694.
41. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M et al (2007). Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46: 242-253. (Pubitemid 47171941)
42. Trebicka J, Leifeld L, Hennenberg M, Eckhardt A, Fischer A, Biecker E et al. (2008). Hemodynamic effects of urotensin II and Its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47:12641276. (Pubitemid 351547913)
43. Tsai MH (2007). Splanchnic and systemic vasodilation. The patient. J. Clin Gastroenterol 41: 266-266
44. Tugues S, Fernandez-Varo G, Munoz-Lugue J, Ros J, Arroyo V, Rodes J et al. (2007). Antiangiogenetic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46: 1919-1926.
45. Van de Casteele M, Sägesser H, Zimmermann H, Reichen J (2001). Characterization of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Therap 90: 35-43. (Pubitemid 32622839)
46. Veronese ML, Mbsenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al (2006). Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 9: 1363-1369. (Pubitemid 46621999)
47. Wiest R (2007). Splanchnic and systemic vasodilation. The experimental models. J. Clin Gastroenterol 41: S272-S287.
48. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA et al (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery 5: 835844. (Pubitemid 44480537)
49. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008). Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet. Oncology 9: 117-123.
50. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E et al (2006). Intrahepatic upregulation of RhoA and Rho-kinase signaling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 55: 1296-1305. (Pubitemid 44277362)